Factor V Leiden Deficiency Icd 10 Code

Factor V Leiden deficiency ICD-10 code is a critical classification used in medical billing and epidemiology to identify individuals with the hereditary thrombophilia known as Factor V Leiden mutation. On the flip side, this genetic alteration increases the risk of abnormal blood clot formation, particularly venous thromboembolism, and is one of the most common inherited clotting disorders worldwide. Understanding the specific ICD-10 code associated with Factor V Leiden deficiency helps clinicians, coders, and researchers track prevalence, allocate resources, and implement appropriate preventive strategies. The following sections provide a comprehensive overview of the condition, its genetic basis, the exact ICD-10‑CM code, diagnostic approaches, management options, and frequently asked questions to support both healthcare professionals and patients seeking reliable information Small thing, real impact..

Short version: it depends. Long version — keep reading.

What Is Factor V Leiden Deficiency?

Factor V Leiden refers to a point mutation in the F5 gene, where guanine is replaced by adenine at position 1691 (G1691A), resulting in the substitution of arginine with glutamine at amino acid position 506 (Arg506Gln). This altered Factor V protein is resistant to inactivation by activated protein C (APC), a natural anticoagulant that normally degrades Factor Va. As a result, thrombin generation remains elevated, promoting a prothrombotic state. Individuals who are heterozygous for the mutation have a moderately increased risk of venous thrombosis, whereas homozygous carriers face a substantially higher risk, although many never experience a clot due to the influence of other genetic and environmental factors.

The condition is termed a “deficiency” in the ICD-10 system not because Factor V levels are low, but because the functional activity of the protein is deficient with respect to APC regulation. This distinction is important for accurate coding and clinical interpretation Practical, not theoretical..

ICD-10‑CM Code for Factor V Leiden Deficiency

The official ICD-10‑CM code for Factor V Leiden deficiency is D68.2. This code falls under the chapter “Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism” (Chapter III) and more specifically within the block “Other coagulation defects” (D65‑D69).

• D68.2 – Hereditary deficiency of other clotting factors
  • Includes: hereditary Factor V Leiden resistance to activated protein C
  • Excludes: acquired resistance to activated protein C (R80.0), disseminated intravascular coagulation (D65), and other specified coagulation defects (D68.8)

When documenting a patient’s medical record, the coder should use D68.2 for any encounter where the Factor V Leiden mutation is confirmed, whether the patient is asymptomatic, undergoing evaluation for thrombotic events, or receiving prophylactic treatment. If the patient presents with an active venous thromboembolism (VTE) such as deep vein thrombosis (DVT) or pulmonary embolism (PE), additional codes from the I80‑I82 series (e.g.Consider this: , I80. 2 for DVT of proximal lower extremity, I26.9 for unspecified pulmonary embolism) should be appended to capture the acute condition alongside the underlying genetic risk Easy to understand, harder to ignore..

Clinical Significance and Associated Risks

Carrying the Factor V Leiden mutation does not guarantee a thrombotic event, but it elevates the baseline risk. Key points to consider include:

• Relative risk: Heterozygotes have approximately 3‑ to 8‑fold increased risk of first VTE compared with non‑carriers; homozygotes may have up to 80‑fold increased risk.
• Situational triggers: Pregnancy, estrogen‑containing oral contraceptives, hormone replacement therapy, surgery, prolonged immobilization, and malignancy can markedly amplify thrombotic risk in carriers.
• Pregnancy considerations: Women with Factor V Leiden face a higher likelihood of recurrent miscarriage, placental infarction, and preeclampsia, particularly when combined with other thrombophilic defects.
• Arterial thrombosis: The mutation is primarily linked to venous events; its role in arterial thrombosis (e.g., myocardial infarction, stroke) remains controversial and generally considered weak compared with venous risk.

Understanding these associations enables clinicians to tailor counseling, screening, and preventive measures based on individual risk profiles Which is the point..

Diagnostic Approach and Laboratory Testing

Diagnosis of Factor V Leiden deficiency relies on molecular genetic testing rather than routine coagulation assays, because standard clotting times (PT, aPTT) are typically normal. The diagnostic workflow generally includes:

1. Clinical suspicion – Personal or family history of unprovoked VTE, early-onset thrombosis (<45 years), recurrent VTE, or thrombosis in unusual sites (e.g., cerebral sinus, mesenteric veins).
2. Initial screening – Activated protein C resistance (APCR) assay using aPTT‑based test. A low APC sensitivity ratio suggests possible Factor

Diagnostic Approach and Laboratory Testing (Continued)

2. Confirmatory testing – When APCR is abnormal, definitive diagnosis requires DNA analysis to identify the specific Factor V G1691A (R532Q) mutation. This molecular confirmation distinguishes true Factor V Leiden from other causes of activated protein C resistance, such as prothrombin G20210A mutation or antiphospholipid syndrome Most people skip this — try not to..

3. Timing considerations – Testing should ideally be performed when the patient is not acutely thrombotic or anticoagulated, as these conditions can temporarily alter results. That said, in emergency settings with high clinical suspicion, initial screening may proceed with plans for confirmatory testing once stabilized.

4. Family screening – After confirming Factor V Leiden in a proband, targeted screening of first-degree relatives may be considered, particularly in families with strong thrombotic histories or when results would influence clinical management decisions.

Management Strategies

Management focuses on risk stratification and individualized anticoagulation decisions:

Acute VTE treatment – Initial management follows standard VTE protocols with low-molecular-weight heparin, unfractionated heparin, or direct oral anticoagulants (DOACs). Treatment duration depends on whether the thrombotic event was provoked or unprovoked, with longer courses typically recommended for unprovoked events in Factor V Leiden carriers Most people skip this — try not to. No workaround needed..

Secondary prevention – Long-term anticoagulation with warfarin, DOACs, or aspirin may be indicated based on recurrence risk assessment. Homozygous carriers generally require more aggressive prevention strategies.

Situational prophylaxis – Perioperative and perinatal periods require enhanced thromboprophylaxis with mechanical methods (compression devices, early ambulation) and pharmacological prophylaxis (low-dose heparin) when bleeding risk permits.

Lifestyle modifications – Smoking cessation, weight optimization, and avoidance of estrogen-containing medications when possible reduce modifiable risk factors.

Coding Documentation Guidelines

Accurate coding requires clear documentation linking the genetic finding to clinical context. That's why the ICD-10 code D68. 2 should be assigned whenever Factor V Leiden is identified, regardless of symptom status, as it represents a definitive genetic diagnosis But it adds up..

• Current or historical VTE events using appropriate I80-I82 series codes
• Complications during pregnancy (O03-O07, O13-O14) when applicable
• Other associated conditions such as recurrent pregnancy loss (N97.1)

Coders must ensure specificity in laterality and anatomical location when assigning VTE codes, and should query clinicians when documentation lacks clarity regarding the relationship between Factor V Leiden and clinical manifestations.

Conclusion

Factor V Leiden mutation represents the most common inherited thrombophilia, requiring nuanced clinical approach and precise coding practices. Because of that, while heterozygous carriers face moderate risk elevation, homozygous individuals warrant intensive monitoring and preventive strategies. In practice, healthcare providers must balance thrombotic risk reduction with bleeding complications through individualized management plans. Proper documentation and coding ensure appropriate care coordination, enable research tracking, and support quality metrics related to thrombophilia management. As personalized medicine advances, understanding genetic risk factors like Factor V Leiden becomes increasingly critical for optimizing patient outcomes and resource allocation in thrombotic disorder prevention and treatment.

Here's a thinking process:

1. Analyze User Input:

• User wants me to "Continue the article without friction."
• "Do not repeat previous text."
• "Finish with a proper conclusion."
• The provided text ends with "## Conclusion" and a paragraph that starts with "Factor V Leiden mutation represents the most common inherited thrombophilia..."
• Wait, the text actually already has a "## Conclusion" section at the end. The user says "Continue the article smoothly. Do not repeat previous text. Finish with a proper conclusion."
• This is a bit tricky. The text provided already ends with a conclusion. Maybe they want me to add something after that, or perhaps they want me to rewrite/generate a continuation that leads to a conclusion, but they explicitly say "Do not repeat previous text" and "Finish with a proper conclusion."
• Let me read the input carefully. It ends with "## Conclusion" and then the conclusion text. The user might be asking me to continue beyond what's given, or maybe they want me to generate a new conclusion or additional section, but they say "Finish with a proper conclusion."
• Perhaps the user wants me to add content after the existing conclusion, or maybe they want me to produce a continuation that naturally extends the article and ends with a conclusion (replacing or augmenting the existing one). But they said "Do not repeat previous text."
• I think the most reasonable interpretation: The user pasted an article that already has a conclusion, but wants me to continue it beyond that point, or perhaps they want me to generate a new section/conclusion that follows without friction without repeating what's already there. Since they explicitly say "Finish with a proper conclusion," I should probably add a new concluding paragraph or section after the existing one, or maybe replace the existing conclusion with a new one, but without repeating the exact text.
• Actually, re-reading: "Continue the article naturally. Do not repeat previous text. Finish with a proper conclusion." This could mean: the text provided is the article so far, and I need to continue it, and end the whole piece with a conclusion. But the provided text already has a "## Conclusion" section. Maybe I should ignore the "## Conclusion" label and add content after it, or perhaps the user made a mistake and wants me to complete the article from where it left off, ending with a conclusion.
• Let me look at the structure: It ends with "As personalized medicine advances, understanding genetic risk factors like Factor V Leiden becomes increasingly critical for optimizing patient outcomes and resource allocation in thrombotic disorder prevention and treatment." That's the last sentence of the existing conclusion.
• If I'm supposed to "continue the article easily" and "finish with a proper conclusion," maybe they want me to add another section or paragraph after the existing conclusion, or perhaps they want me to generate a new conclusion that replaces the old one but doesn't repeat it. Given the strict instruction "Do not repeat previous text," I should not copy-paste or rephrase the existing conclusion. I should add new content.
• I think the best approach: Provide a seamless continuation that adds value, perhaps focusing on emerging therapies, patient education, or future directions, and then end with a fresh conclusion that wraps up the entire article without repeating the exact wording of the provided conclusion.
• Wait, maybe the user wants me to simply continue from where the text ended, but the text already ended with a conclusion. Perhaps I should output a new conclusion or a post-conclusion section. To be safe, I'll add a new section or paragraph after the existing text, ensuring I don't repeat it, and end with a proper concluding sentence/paragraph.
• Let me re-read the user's prompt: "Continue the article naturally. Do not repeat previous text. Finish with a proper conclusion." This likely means: The text provided is the beginning/middle, and I need to continue it and end the whole article with a conclusion. But the text already has a "## Conclusion" at the very end. Maybe the user didn't notice or wants me to add onto it. I'll treat the provided text as the part I need to continue from, and I'll add new content after it, then finish with a conclusion. But the last line is already a conclusion. I could add a new paragraph after "## Conclusion" or replace it with a new one, but I must not repeat previous text.
• I'll generate a continuation that starts after the existing text, perhaps a new section on "Future Directions" or "Patient-Centered Care," and then provide a fresh conclusion that ties everything together, ensuring no repetition of the exact phrases from the given conclusion.
• Actually, to be most seamless: I'll continue the article from where the provided text left off, but since it already ended with a conclusion, I'll add a new paragraph or section after it, and then end with a concluding statement. But the user said "Finish with a proper conclusion," which might mean the entire output should end with a conclusion. I'll provide a new conclusion that follows smoothly from the article's content, without repeating the previous conclusion's exact words.
• Let me draft: I'll add a new section or paragraph that continues the theme, then end with a concise conclusion. To follow "Do not repeat previous text," I'll make sure the wording is entirely new.
• Plan:
  • I'll output a continuation that adds value, perhaps focusing on emerging research, genetic counseling, or integrated care models.
  • Then I'll provide a proper conclusion that wraps up the article, ensuring it's not a repetition of the given conclusion.
  • I'll make sure the transition is seamless